SELECT trials: Weight Loss Drug Wegovy Shows Promise in Protecting Heart Health

Wegovy has demonstrated its potential to reduce the risk of heart attacks, strokes, and heart disease-related deaths.

Protecting Heart Health:

For the first time, a weight loss drug has shown the ability to independently lower the risk of heart-related issues in people without diabetes. This is a remarkable achievement and could reshape how obesity and its associated risks are approached and treated.

In an exciting breakthrough, the weight loss drug Wegovy has demonstrated its potential to reduce the risk of heart attacks, strokes, and heart disease-related deaths by a significant 20% in a major clinical trial. This groundbreaking study, known as "SELECT," focused on individuals with cardiovascular disease who were overweight or obese but did not have diabetes. Here's what you need to know about this game-changing development:

Study Details:

Novo Nordisk, the company behind Wegovy, conducted a five-year trial involving 17,604 adults with heart disease and excess weight. Participants were divided into groups receiving either Wegovy or a placebo, in addition to standard care. The study's findings are particularly noteworthy, as they reveal a higher level of heart risk reduction than anticipated.

The positive outcomes of the Select trial could lead to improved insurance coverage for weight loss medications like Wegovy, in countries such as the US. This would be a significant step forward, making these treatments more accessible to individuals struggling with obesity.

Experts believe that these findings will underscore the importance of weight loss as a meaningful health goal, not just a cosmetic aspiration. Medical professionals foresee an increased willingness among insurers to cover medications that aid in weight reduction.

What's Next:

Novo Nordisk is planning to submit applications to regulatory agencies to include the cardiovascular benefits of Wegovy in its prescribing information. This step is crucial for securing better insurance coverage. Additionally, the company intends to present comprehensive results from the SELECT trial at a scientific conference later this year.

As the medical community eagerly awaits more detailed insights from this landmark trial, it's clear that Wegovy's potential extends far beyond weight loss. The impact on heart health could pave the way for more effective treatments and improved quality of life for individuals struggling with obesity and related conditions.

Published: 8 August 2023